• Categories:Policies & Regulations
• Time of issue:2018-11-10

(Summary description)Recently, the editor found that many pig farmers are very happy, so I wondered, why is this?! Until, the editor learned such a blockbuster news: November 6, 2018, which took 8 years of research and development. The launch conference of the water adjuvant porcine circovirus type 2 and Mycoplasma hyopneumoniae dual inactivated vaccine was held in Luoyang.     It is understood that this water adjuvant porcine circovirus type 2 and Mycoplasma hyopneumoniae dual inactivated vaccine was developed by Luoyang Huizhong Biotechnology Co., Ltd. relying on the National Veterinary Medicine Engineering Technology Research Center. It mainly solves the problem of pig breeding. The two major epidemic prevention problems for households allow pig farmers to invest less and make more profits when raising epidemic prevention pigs! "Porcine circovirus type 2 and Mycoplasma hyopneumoniae dual inactivated vaccine" is Huizhong Biotechnology Co., Ltd. adhering to the business philosophy of "decent and stable operation", pursuing the development strategy of "innovating for the future" and relying on the national veterinary drug project. The Technology Research Center has achieved major scientific and technological achievements for the technology platform, has independent intellectual property rights, and has obtained the national new veterinary drug registration certificate. This result is another masterpiece achieved through continuous innovative practice since Huizhong's biological adjuvant porcine circovirus type 2 inactivated vaccine (SH strain II)!   Huizhong Biological Water Adjuvant Porcine Circovirus Type 2 Inactivated Vaccine (SH strain II), leading the domestic water adjuvant whole virus inactivated vaccine, has played a major role in the prevention and control of my country's porcine circovirus disease since the product was successfully launched , Creating good economic and social benefits; relying on the National Veterinary Medicine Engineering Technology Research Center, the company continues to carry out research and development and technological innovation and upgrades for the prevention and control of the epidemic, and develops newer and safer vaccines. The project team used special water adjuvants and advanced seedling production technology to effectively avoid the risks of adjuvant, antigen incompatibility, stability and uniformity after single seedlings were mixed, and successfully isolated, evaluated and screened Mycoplasma strains with good immunogenicity and growth. Developed a safe and efficient water-based adjuvant suitable for two antigens, solved the three major technical problems of compatibility between PCV2 and mycoplasma antigens, and successfully developed domestic water adjuvants, porcine circovirus type 2, and mycoplasma hyopneumoniae II. Combined inactivated vaccine. The successful development and listing of this product is of great practical significance for promoting technological progress and product upgrades in the industry, and improving the level of disease prevention and control. No wonder the pig farmers are so happy, one shot and two defenses, to increase the survival rate of pigs, so that each pig can make more money. If you are not happy, it is strange!